Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0HA0U
|
|||
| Former ID |
DNC008415
|
|||
| Drug Name |
12-dehydroxyriccardin C
|
|||
| Synonyms |
12-dehydroxyriccardin C; Riccardin C derivative, 20c; CHEMBL260632; BDBM23850; 2',4-[Ethylene-1,4-phenylene-oxy-(6-hydroxy-1,3-phenylene)-ethylene]-1,1'-biphenyl-4'-ol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H24O3
|
|||
| Canonical SMILES |
C1CC2=CC(=C(C=C2)O)OC3=CC=C(CCC4=C(C=CC(=C4)O)C5=CC=C1C=C5)C=C3
|
|||
| InChI |
1S/C28H24O3/c29-24-12-15-26-22-9-3-19(4-10-22)1-2-21-8-16-27(30)28(17-21)31-25-13-6-20(7-14-25)5-11-23(26)18-24/h3-4,6-10,12-18,29-30H,1-2,5,11H2
|
|||
| InChIKey |
VSXIMYQGZUVRSK-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oxysterols receptor LXR-alpha (NR1H3) | Target Info | Inhibitor | [1] |
| Oxysterols receptor LXR-beta (NR1H2) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | PPAR signaling pathway | |||
| Non-alcoholic fatty liver disease (NAFLD) | ||||
| Hepatitis C | ||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
| Reactome | Nuclear Receptor transcription pathway | |||
| WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
| Nuclear Receptors Meta-Pathway | ||||
| PPAR Alpha Pathway | ||||
| Liver X Receptor Pathway | ||||
| Adipogenesis | ||||
| SREBF and miR33 in cholesterol and lipid homeostasis | ||||
| Nuclear Receptors | ||||
| SREBP signalling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.